Association of aging and obesity with decreased 17-hydroxyprogesterone, a serum biomarker of intratesticular testosterone.
Journal
International journal of impotence research
ISSN: 1476-5489
Titre abrégé: Int J Impot Res
Pays: England
ID NLM: 9007383
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
10
06
2020
accepted:
21
09
2020
pubmed:
4
10
2020
medline:
23
2
2022
entrez:
3
10
2020
Statut:
ppublish
Résumé
Obesity's negative association with serum testosterone can be explained by either decreasing luteinizing hormone (LH) production from the pituitary gland and/or directly impacting intratesticular testosterone production. We hypothesize that obesity will negatively impact intratesticular testosterone levels when compared to those of non-obese men. We performed a cross-sectional analysis of men with symptoms of testosterone deficiency and male infertility between July 2018 and April 2020 to evaluate the association between body mass index (BMI) and age with intratesticular testosterone (using serum 17-hydroxyprogesterone (17-OHP) as a biomarker), and between BMI with LH. Univariable and multiple linear regression analysis were performed using confounding variables to predict 17-OHP and testosterone. A total of 340 men were selected. Median age was 38 [33-44] years, BMI 27.8 [25.4-31.1] kg/m
Identifiants
pubmed: 33009497
doi: 10.1038/s41443-020-00358-8
pii: 10.1038/s41443-020-00358-8
doi:
Substances chimiques
Biomarkers
0
Testosterone
3XMK78S47O
17-alpha-Hydroxyprogesterone
68-96-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
44-49Informations de copyright
© 2020. The Author(s), under exclusive licence to Springer Nature Limited.
Références
The Centers for Disease Control and Prevention. https://www.cdc.gov/nchs/products/databriefs/db360.htm . Accessed 26 Apr 2020.
Allen NE, Appleby PN, Davey GK, Key TJ. Lifestyle and nutritional determinants of bioavailable androgens and related hormones in British men. Cancer Causes Control. 2002;13:353–63.
doi: 10.1023/A:1015238102830
Lokeshwar SD, Patel P, Fantus RJ, Halpern J, Chang C, Kargi AY, et al. Decline in serum testosterone levels among adolescent and young adult men in the USA. Eur Urol Focus. 2020. https://doi.org/10.1016/j.euf.2020.02.006 .
Jensen TK, Andersson AM, Jørgensen N, Andersen AG, Carlsen E, Petersen JH, et al. Body mass index in relation to semen quality and reproductive hormones among 1,558 Danish men. Fertil Steril. 2004;82:863–70.
doi: 10.1016/j.fertnstert.2004.03.056
Svartberg J, von Mühlen D, Sundsfjord J, Jorde R. Waist circumference and testosterone levels in community dwelling men. The Tromsø Study. Eur J Epidemiol. 2004;19:657–63.
doi: 10.1023/B:EJEP.0000036809.30558.8f
Glass AR, Swerdloff RS, Bray GA, Dahms WT, Atkinson RL. Low serum testosterone and sex-hormone-binding-globulin in massively obese men. J Clin Endocrinol Metab. 1977;45:1211–9.
doi: 10.1210/jcem-45-6-1211
Zumoff B, Strain GW, Miller LK, Rosner W, Senie R, Seres DS, et al. Plasma free and non sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab. 1990;71:929–31.
doi: 10.1210/jcem-71-4-929
Pasquali R, Casimirri F, Cantobelli S, Melchionda N, Morselli Labate AM, Fabbri R, et al. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism. 1991;40:101–4.
doi: 10.1016/0026-0495(91)90199-7
Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154:899–906.
doi: 10.1530/eje.1.02166
Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med. 2013;10:1612–27.
doi: 10.1111/jsm.12146
Lima TFN, Patel P, Blachman-Braun R, Madhusoodanan V, Ramasamy R. Serum 17-hydroxyprogesterone is a potential biomarker for evaluating intratesticular testosterone. J Urol. 2020. 101097JU0000000000001016.
Patel A, Patel P, Bitran J, Ramasamy R. Can serum 17-hydroxyprogesterone and insulin-like factor 3 be used as a marker for evaluation of intratesticular testosterone? Transl Androl Urol. 2019;8:S58–63.
doi: 10.21037/tau.2019.01.16
Amory JK, Coviello AD, Page ST, Anawalt BD, Matsumoto AM, Bremner WJ. Serum 17-hydroxyprogesterone strongly correlates with intratesticular testosterone in gonadotropin-suppressed normal men receiving various dosages of human chorionic gonadotropin. Fertil Steril. 2008;89:380–6.
doi: 10.1016/j.fertnstert.2007.02.059
Chen H, Ge RS, Zirkin BR. Leydig cells: from stem cells to aging. Mol Cell Endocrinol. 2009;306:9–16.
doi: 10.1016/j.mce.2009.01.023
The Centers for Disease Control and Prevention. https://www.cdc.gov/obesity/adult/defining.html . Accessed 26 Apr 2020.
Kort HI. Impact of body mass index values on sperm quantity and quality. J Androl. 2006;27:450–2.
doi: 10.2164/jandrol.05124
Khodamoradi K, Parmar M, Khosravizadeh Z, Kuchakulla M, Manoharan M, Arora H. The role of leptin and obesity on male infertility. Curr Opin Urol. 2020;30:334–9.
doi: 10.1097/MOU.0000000000000762
Katib A. Mechanisms linking obesity with male infertility. Cent European J Urol. 2015;68. https://doi.org/10.5173/ceju.2015.01.435.
Zirkin BR, Santulli R, Awoniyi CA, Ewing LL. Maintenance of advanced spermatogenic cells in the adult rat testis: quantitative relationship to testosterone concentration within the testis. Endocrinology. 1989;124:3043.
doi: 10.1210/endo-124-6-3043
Jarow JP, Kirkland J, Koritnik DR, Cefalu WT. Effect of obesity and fertility status on sex steroid levels in men. Urology. 1993;42:171–4.
doi: 10.1016/0090-4295(93)90641-M
Tenover J. Declining testicular function in aging men. Int J Impot Res. 2003;15:S3–8.
doi: 10.1038/sj.ijir.3901029
Sallmén M, Sandler DP, Hoppin JA, Blair A, Baird DD. Reduced fertility among overweight and obese men. Epidemiology. 2006;17:520–3. https://doi.org/10.1097/01.ede.0000229953.76862.e5 .
doi: 10.1097/01.ede.0000229953.76862.e5.
pubmed: 16837825
Isidori AM, Caprio M, Strollo F, Moretti C, Frajese G, Isidori A, et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab. 1999;84:3673–80.
pubmed: 10523013
Fui MN, Dupuis P, Grossmann M. Lowered testosterone in male obesity: mechanisms, morbidity and management. Asian J Androl. 2014;16:223–31.
doi: 10.4103/1008-682X.122365
Paduch DA, Brannigan RE, Fuchs EF, Kim ED, Marmar JL, Sandlow JI. The laboratory diagnosis of testosterone deficiency. Urology. 2014;83:980.
doi: 10.1016/j.urology.2013.12.024
Blanchette S, Marceau P, Biron S, Brochu G, Tchernof A. Circulating progesterone and obesity in men. Horm Metab Res. 2006;38:330–5.
doi: 10.1055/s-2006-925392